CFS™
chemo

Resources

Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Earn up to 3.0 AMA PRA Category 1 Credits™
The optimal care of patients with cancer is rapidly changing as a result of advances in all state-of-the-art cancer care, and continues to evolve due to advances in all aspects of patient care, including diagnosis and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular-targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® (CFS) has brought together over 2000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 33 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 33rd Annual CFS, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty provided continued insights on new developments in cancer therapeutics, and offered oncology professionals an opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of controlling and curing cancer.

This activity contains a series of clinical vignettes--focused on myeloma, chronic lymphocytic leukemia, lung cancer, and breast cancer--that illustrate the application of data and expert insights from the 2015 CFS in realistic case scenarios that reinforce key learning points from the conference, and facilitate application of these findings to clinical practice to improve patient care.

PER Pulse™ Recap
PER Pulse™ Recaps for Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspective on case management decisions is provided in these summaries.



PER Pulse™ Recap
PER Pulse™ Recap


1 of 3
PER Pulse™ Recap
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is a series of short video interviews with faculty from the live 33rd Annual Chemotherapy Foundation Symposium, who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented at the Symposium. The activity features discussion on:

  • Newly diagnosed multiple myeloma (MM), by Sagar Lonial, MD
  • Newly diagnosed chronic lymphocytic leukemia (CLL), by Susan M. O’Brien, MD
  • Metastatic lung adenocarcinoma, by Heather A. Wakelee, MD
  • Metastatic squamous cell carcinoma of the lung, by Naiyer A. Rizvi, MD
  • Neoadjuvant therapy for triple-negative breast cancer (TNBC), by Debu Tripathy, MD
  • Germline testing for TNBC by Mark E. Robson, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Lonial’s answers to questions about important factors in treatment decision making for newly diagnosed MM, the current role of risk assessment and the Revised International Staging System (R-ISS), strategies for monitoring patients post-induction and post-transplant, and the importance of achieving minimal residual disease (MRD) in MM. During his interview, Dr. Lonial will:

  • Explain that when evaluating the transplant eligibility of a patient newly diagnosed with MM, he considers whether the patient is fit or frail. If a patient is fit, age may not be relevant to transplant eligibility. However, frail patients may not be suitable candidates for transplant or for 3-drug regimens.
  • Suggest that an immunomodulatory drug/protease inhibitor‒based triplet regimen (eg, lenalidomide-bortezomib-dexamethasone) be used for induction, and will refer to pending data demonstrating the superiority of triplet regimens over cyclophosphamide-based induction.
  • Note that evidence supports use of lenalidomide-dexamethasone or a bortezomib-based doublet for frail patients who are ineligible for transplant.
  • Recommend against use of MRD for treatment decision making until more data are available.
  • Share his perspectives on the future of 4-drug regimens for MM.

2 of 3
PER Pulse™ Recap
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is a series of short video interviews with faculty from the live 33rd Annual Chemotherapy Foundation Symposium, who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented at the Symposium. The activity features discussion on:

  • Newly diagnosed multiple myeloma (MM), by Sagar Lonial, MD
  • Newly diagnosed chronic lymphocytic leukemia (CLL), by Susan M. O’Brien, MD
  • Metastatic lung adenocarcinoma, by Heather A. Wakelee, MD
  • Metastatic squamous cell carcinoma (SCC) of the lung, by Naiyer A. Rizvi, MD
  • Neoadjuvant therapy for triple-negative breast cancer (TNBC), by Debu Tripathy, MD
  • Germline testing for TNBC, by Mark E. Robson, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on interviews with Drs. Rizvi and Wakelee about modern clinical strategies for metastatic lung adenocarcinoma and SCC:

  • Dr. Wakelee discusses her approach for a 77-year-old male with a 15 pack-year history of smoking who presented with persistent cough and dyspnea on exertion, and was found to have TTF1-positive, metastatic adenocarcinoma (left lower lobe mass, 3 liver lesions, left adrenal mass, and multiple bony metastases).
  • Dr. Wakelee also shares her perspective on a variety of issues, including ensuring ample biopsy material for histologic and molecular stains; testing beyond ROS1, EGFR, and ALK; using liquid biopsies for lung cancer, and selecting therapy when the oncogenic driver mutation is unknown.
  • Dr. Rizvi talks about his approach for a 62-year-old female with a 60 pack-year smoking history who underwent concurrent chemoradiation therapy (cisplatin/etoposide) for stage IIIB squamous non-small cell lung cancer (NSCLC), and who developed recurrent lung disease and bone metastases 18 months later.
  • Dr. Rizvi also discusses a variety of related topics, including molecular testing of SCC; including PD-L1 expression testing), the International Association for the Study of Lung Cancer (IASLC) Blueprint project, the role of checkpoint inhibitors, and clinical challenges with checkpoint inhibitors (eg, adverse events, pseudoprogression).

3 of 3
PER Pulse™ Recap
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is a series of short video interviews with faculty from the live 33rd Annual Chemotherapy Foundation Symposium, who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented at the Symposium. The activity features discussion on the following:

  • Newly diagnosed multiple myeloma (MM), by Sagar Lonial, MD
  • Newly diagnosed chronic lymphocytic leukemia (CLL), by Susan M. O’Brien, MD
  • Metastatic lung adenocarcinoma, by Heather A. Wakelee, MD
  • Metastatic squamous cell carcinoma (SCC) of the lung, by Naiyer A. Rizvi, MD
  • Neoadjuvant therapy for triple-negative breast cancer (TNBC), by Debu Tripathy, MD
  • Germline testing for TNBC, by Mark E. Robson, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on interviews with Drs. Tripathy and Robson:

  • Dr. Tripathy discusses his approach toward neoadjuvant therapy and follow-up for a 65-year-old female who was diagnosed with stage II TNBC (clinical size 3 cm, ALN+).
  • Throughout his discussion of this case, Dr. Tripathy shares his perspectives on a variety of issues, such as monitoring response to neoadjuvant therapy, treating stable disease after completion of doxorubicin and cyclophosphamide (AC), managing locoregional recurrence, interpreting complete pathologic response as an endpoint in the neoadjuvant setting, and investigational treatment regimens.
  • Dr. Robson talks about his approach for a 33-year-old woman who presents with a 2-cm mass in her left breast that is found to be triple-negative, poorly differentiated, invasive ductal cancer by core needle biopsy.
  • While discussing the case, Dr. Robson elaborates on genetic testing for patients with and without familial breast cancer risk factors, genetic aberrations he considers significant, first-line locoregional and systemic treatment standards, and key points regarding bilateral mastectomy to discuss with patients during decision making.


Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Supported by educational grants from Astellas Pharma, AstraZeneca, Boston Biomedical Pharma, Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis, Incyte Corporation, Ipsen Biopharmaceuticals, Inc, Lilly, Merck & Co, Inc, Merrimack Pharmaceuticals, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics, Inc, and Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, Puma Biotechnology, Taiho Oncology, Inc, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

 


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By